Medication and glycemic control

Journal articles and book chapters

11-03-2018 | Liraglutide (T2DM) | Article

Liraglutide and glycemic outcomes in the LEADER trial

Zinman B et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0524-z

09-14-2018 | Insulin glargine/Lixisenatide | Article

Bedtime-to-morning glucose difference and iGlarLixi in type 2 diabetes: Post hoc analysis of LixiLan-L

Zisman A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0507-0

09-13-2018 | Pramlintide acetate | Article

Control of postprandial hyperglycemia in type 1 diabetes by 24-hour fixed-dose coadministration of pramlintide and regular human insulin: A randomized, two-way crossover study

Riddle MC et al. Diabetes Care 2018: dc181091. doi: 10.2337/dc18-1091

09-10-2018 | Insulin glargine | Article

Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis

Twigg SM et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0498-x

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

08-21-2018 | Dulaglutide | Article

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulfonylurea: A 52‐week open‐label, randomized phase 3 trial

Wang W et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13506

08-20-2018 | Insulin pumps | Article

Real‐world outcomes of insulin pump compared to injection therapy in a population based sample of children with type 1 diabetes

Burckhardt MA et al. Pediatr Diabetes 2018. doi: 10.1111/pedi.12754

08-18-2018 | Continuous glucose monitoring | Review | Article

Prevention and management of severe hypoglycemia and hypoglycemia unawareness: Incorporating sensor technology

Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6

08-18-2018 | Medications | Article

Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: A network meta-analysis

Qian D et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0482-5

08-17-2018 | Medications | Review | Article

Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes

Tosur M, Redondo MJ, Lyons SK. Curr Diab Rep 2018; 18: 79. doi: 10.1007/s11892-018-1041-1

08-16-2018 | DPP-4 inhibitors | Review | Article

Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios

Gomez-Peralta F et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0488-z

08-15-2018 | Nephropathy | Review | Article

Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis

Iyengar R, Franzese J, Gianchandani R. Curr Diab Rep 2018; 18: 75. doi: 10.1007/s11892-018-1044-y

08-15-2018 | Type 2 diabetes | Article

Time to treatment intensification after monotherapy failure and its association with subsequent glycemic control among 93,515 patients with type 2 diabetes

Desai U et al. Diabetes Care 2018: dc170662. doi: 10.2337/dc17-0662

08-13-2018 | Insulin glargine | Article

More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: The randomized head-to-head BRIGHT trial

Rosenstock J et al. Diabetes Care 2018: dc180559. doi: 10.2337/dc18-0559

07-28-2018 | Dulaglutide | Article

Durability of glucose-lowering effect of the first administration of dulaglutide: A retrospective, single-center, single-arm study

Matsushita M et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0474-5

07-20-2018 | Insulin pumps | Article

Optimizing a hybrid closed loop system in type 1 diabetes: A case report

The authors present the optimization of a hybrid closed-loop insulin pump system in an 11-year-old female with 7 years of type 1 diabetes.

Petrovski G et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0473-6

07-19-2018 | Dapagliflozin | Article

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial

Methieu C et al. Diabetes Care 2018: dc180623. doi: 10.2337/dc18-0623

07-03-2018 | Hypoglycemia | Article

Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes

Lipska KJ et al. JAMA 2018; 320: 53–62. doi: 10.1001/jama.2018.7993

06-30-2018 | Insulin NPH | Article

Glycemic control in hospitalized patients with diabetes receiving corticosteroids using a neutral protamine Hagedorn insulin protocol: A randomized clinical trial

Khowaja A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0468-3